Jornal de Ensaios Clínicos sobre Câncer

The Mechanisms of Action and Emerging Novel Views on SGLT-2 Inhibitors in the Treatment of Cancer

Abstract

Ava Moreno

Sodium-Glucose Co-Transporter-2 (SGLT-2) inhibitors, originally developed for managing diabetes mellitus, have recently garnered attention for their potential anti-cancer properties. This comprehensive review explores the mechanisms of action of SGLT-2 inhibitors and examines emerging novel perspectives on their role in cancer treatment. We delve into the metabolic alterations induced by these inhibitors, their impact on the tumor microenvironment, and their effects on cancer cell proliferation and survival. Furthermore, we discuss recent preclinical and clinical studies highlighting the therapeutic potential of SGLT-2 inhibitors in various cancer types. This article aims to provide a holistic understanding of the current state of research and future directions for SGLT-2 inhibitors in oncology.